Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:allocates |
randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:clinicalTrialsGovIdentifier |
NCT03730662
|
| gptkbp:conditionStudied |
gptkb:type_2_diabetes
|
| gptkbp:enrollment |
~2,002 participants
|
| gptkbp:fullName |
A Study of Tirzepatide (LY3298176) Versus Insulin Glargine on Major Cardiovascular Events in Participants With Type 2 Diabetes
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURPASS-4
|
| gptkbp:intervention |
gptkb:insulin
gptkb:tirzepatide |
| gptkbp:location |
multinational
|
| gptkbp:mask |
open label
|
| gptkbp:primaryCompletionDate |
2021
|
| gptkbp:publishedIn |
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
|
| gptkbp:purpose |
gptkb:psychotherapy
|
| gptkbp:result |
change in HbA1c
change in body weight |
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2019
|
| gptkbp:status |
completed
|
| gptkbp:studyType |
interventional
|
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|